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Overexpression of insulin-like growth factor-II (IGF2) is a prominent characteristic of many
epithelial ovarian malignancies. IGF2 imprinting and transcription are regulated in part
through DNA methylation, which in turn regulates binding of the insulator protein CTCF
within the IGF2/H19 imprint center. We have shown that IGF2 overexpression in ovarian
cancer is associated with hypermethylation of CTCF binding sites within the IGF2/H19
imprint center.The aim of this study was to investigate the methylation and binding capac-
ity of a novel putative CTCF binding motif located intragenic to IGF2 and determine how
this relates to IGF2 expression. Among 35 primary serous epithelial ovarian cancer speci-
mens, methylation of two CpGs, including one within the core binding motif and another
adjacent to this motif, was higher in the 18 cancers with elevated IGF2 expression versus
10 with low expression (average 68.2 versus 38.5%; p<0.0001). We also found that the
CpG site within the CTCF binding motif is hypermethylated in male gametes (>92%; aver-
age 93.2%; N =16).We confirmed binding of CTCF to this region in ovarian cancer cells, as
well as the paralog of CTCF, Brother Of the Regulator of Imprinted Sites (BORIS), which is
frequently overexpressed in cancers. The unmethylated CTCF binding motif has insulator
activity in cells that express CTCF or BORIS, but not in cells that express both CTCF and
BORIS. These intragenic CpG dinucleotides therefore comprise a novel paternal germline
imprint mark and are located in a binding motif for the insulator protein CTCF. Methylation
of the CpG dinucleotides is positively correlated with IGF2 transcription, indicating that
increased methylation represses insulator function. These combined results suggest that
methylation and CTCF binding at this region play important roles in regulating the level of
IGF2 transcription. Our data have revealed a novel epigenetic regulatory element within the
IGF2/H19 imprinted domain that is highly relevant to aberrant IGF2 expression in ovarian
malignancies.
Keywords: insulin-like growth factor 2, epithelial ovarian cancer,DNAmethylation, chromatin immunoprecipitation,
CTCF, spermatozoa, germline methylation, luciferase reporter assay
INTRODUCTION
Insulin-like growth factor-II (IGF2) encodes a potent autocrine
and paracrine mitogen that is important to early growth and
development (Hoyo et al., 2012; St-Pierre et al., 2012), but is also
often deregulated in cancers, including colon (Cui et al., 2003)
and ovarian cancers (Sayer et al., 2005; Lu et al., 2006; Murphy
et al., 2006; Dammann et al., 2010; Qian et al., 2011) where it has
been shown to modulate taxol response (Huang et al., 2010). The
H19 gene is located adjacent to IGF2 and produces a long non-
coding RNA molecule whose function is not completely under-
stood. Both genes are regulated by genomic imprinting, resulting
in the production of IGF2 transcripts from the paternally derived
chromosome and H19 RNAs from the maternally derived chro-
mosome. Epigenetic marks dictate this pattern of expression, and
are established during gametogenesis in a process that involves
the differential marking of the parental chromosomes with DNA
methylation. These marks are then “read” such that expression
occurs from only one of the two parental alleles, and this pat-
tern of expression and epigenetic marking is stably transmitted
throughout somatic cell division.
Prior studies have determined that a region upstream of theH19
promoter is methylated on the paternally derived chromosome,
while the maternally derived chromosome is hypomethylated.
Within this differentially methylated domain, referred to as the
imprint control region (ICR), are multiple binding sites for the
CCCTC binding factor (CTCF) protein. CTCF is a highly con-
served zinc finger protein that binds to genomic DNA at numerous
sites throughout the genome (Sanyal et al., 2012; Wang et al., 2012)
and has played a key role in the evolutionary diversity of metazoans
(Heger et al., 2012). One of the functions of CTCF is the remodel-
ing of chromatin structure to form insulator elements (Filippova,
2008), and CTCF has been shown to co-localize with cohesin in
the control of chromatin architecture and gene regulation (Lee
and Iyer, 2012). The importance of CTCF binding to genomic
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imprinting was demonstrated by several groups who showed that
CTCF binds the unmethylated maternal chromosome, upstream
of the promoter region of the H19 gene within the ICR. CTCF
binding prevents enhancers downstream from H19 from activat-
ing IGF2 on the maternal chromosome, while the methylation
present on the paternally derived chromosome prevents CTCF
binding. IGF2 transcription is thus positively influenced by the
unencumbered cis-acting enhancer elements (Wolffe, 2000).
Prior studies, including our own, have identified a consensus
binding motif, 5′-CCGCNNGGNGNC-3′ for the CTCF protein
(Wylie et al., 2000; Rosa et al., 2005). We identified a sequence
within IGF2 intron 3 that matches this consensus motif, and our
preliminary analysis showed a strong relationship between methy-
lation of this putative binding site and expression of IGF2 in
ovarian cancer tissues. Herein we examined the methylation sta-
tus of this site, including parental origin, and show that this novel
consensus sequence binds to CTCF and mechanistically functions
as an insulator element in ovarian cancer cells.
MATERIALS AND METHODS
SPECIMENS
De-identified primary ovarian cancer tissues for this study were
obtained from the Duke Gynecologic Oncology Tissue Bank
(DCOTB) under a protocol approved by the Duke University
Institutional Review Board. The DCOTB collects and banks spec-
imens for research purposes following acquisition of informed
written consent from patients undergoing surgery for epithelial
ovarian cancer under a separate protocol approved by the Duke
University Institutional Review Board. Surgical specimens were
processed immediately after removal from the patient and stored
at −80˚C. Human spermatozoa were from the Duke Division of
Reproductive Endocrinology and Fertility and used under a pro-
tocol approved by the Duke Institutional Review Board. Conceptal
tissues were provided as de-identified specimens by the Laboratory
of Developmental Biology at the University of Washington (sup-
ported by NIH Award Number 5R24HD000836 from the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development).
Cell lines were from a collection maintained by the Duke Divi-
sion of Gynecologic Oncology. The genetic authenticity of the
cells used in these studies was determined using microsatellite
marker analysis at the University of Colorado at Denver (Korch
et al., 2012). Cells were grown in RPMI1640 medium (Invitro-
gen) supplemented with 10% fetal bovine serum (Invitrogen)
and penicillin–streptomycin (Invitrogen, Carlsbad, CA, USA) in
a humidified chamber at 37˚C with 5% atmospheric CO2.
DNA EXTRACTION
Tissue culture cells were washed with 1× PBS and collected
after they reached 70–80% confluence. Frozen tumor tissues
were homogenized using a FastPrep SP120 Homogenizer (Bio101
Thermo Savant; Logan, UT) and collected into microcentrifuge
tubes. DNA was extracted using Gentra Puregene Reagents with
protocols provided by the manufacturer specific to the sample type
(Qiagen, Valencia, CA, USA). Quality and quantity of extracted
DNA was evaluated using a Nanodrop 1000 spectrophotome-
ter (Thermo Scientific; Wilmington, DE, USA). Aliquots were
prepared and stored at −80˚C. The A260/A280 absorbance ratios
were >1.8 for all DNA used.
METHYLATION ANALYSIS
Two methods were used for CpG methylation analysis of the IGF2
intragenic region. Quantitative radiolabeled bisulfite sequencing
was used for frozen ovarian cancer tissues. Because of the manu-
facturer’s permanent discontinuation of the radiolabeled isotope
used for quantitative bisulfite sequencing,bisulfite pyrosequencing
was used for all other analyses.
Bisulfite sequencing
Genomic DNA (1µg) was modified with sodium bisulfite as pre-
viously described (Murphy et al., 2003) and eluted in 25µl of
nuclease-free water. Forty nanograms of the bisulfite modified
DNA (assuming complete recovery) was used in a 25µl PCR reac-
tion that included 3 mM MgCl2, 1 mM each dNTP, and 0.4µM
each primer with 1.25 U Platinum Taq (Invitrogen; Carlsbad, CA,
USA). A 290 bp PCR product specific to intron 3 of IGF2 was gen-
erated with primers listed in Table 1. PCR conditions were 94˚C
for 3 min, 35 cycles of 94˚C for 30 s, 62˚C for 30 s, 72˚C for 45 s,
with a final 5 min extension at 72˚C. The amplicons were resolved
by agarose gel electrophoresis, excised, and purified using Sigma
GenElute Spin columns (Sigma Aldrich). Bisulfite sequencing was
performed using the Radiolabeled Terminator Cycle Sequencing
Kit (USB Corporation) according to the manufacturer’s directions.
Sequencing products were resolved by denaturing polyacrylamide
gel electrophoresis and the gels were dried under vacuum followed
Table 1 | Oligonucleotide primers.
Primer Application Sequence (5′–3′)
Int3-IGF2-BS-F Bisulfite sequencing GTTTTTTTGGTTGTGGGATTA
AGAG
Int3-IGF2-BS-R Bisulfite sequencing AACCACACAACAAACAAAAA
AATC
Int3-IGF2-IR-seq Bisulfite sequencing CAAACCACCCCTACCCTC
Int3-CTCF3-PS-F Pyrosequencing TTGGGAAGTTTTTGTTTGTT
AGT
Int3-CTCF3-PS-R Pyrosequencing Biotin-ACCCTCAAACCAAA
CCCTAA
Int3-CTCF3-PS-seq Pyrosequencing GGAAGTTTTTGTTTGTTAGT
Int3-CBS-chip-F Chromatin IP ACTCACCTCCCCTCTCAC
Int3-CBS-chip-R Chromatin IP AGCAAACCACCCCTGCC
MYC-chip-F Chromatin IP CCTGAAAGAATAACAAGGAG
GTGGCTGGAAACTTG
MYC-chip-R Chromatin IP GCAAATTACTCCTGCCTCCA
GGCCTTTG
NheI-CTCF-F2 Luciferase reporter ATATTGCTAGCCACATCCCAC
ACATTTTCCA
R2-CTCF-XhoI Luciferase reporter AAAGCTCGAGGAGAGAGCC
GTGTTAGCAC
GAPDH-SmaI-F Luciferase reporter ATATTAGCCCGGGTGGTCTGA
GGTTAAATATAGC
GAPDH-Bgl II-R Luciferase reporter TAATTGCAGATCTAAGAGACA
AGAGGCAAGAAGG
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by exposure to a storage phosphor screen. Methylation was quan-
tified using the Molecular Dynamics Storm Phosphorimaging
System and ImageQuant software (GE Healthcare; Pittsburgh, PA,
USA). The percent cytosine methylation was calculated as fol-
lows: [CM/(CU+CM)]× 100, where CM is the measurement for
cytosine at a given CpG dinucleotide position and CU is the mea-
surement for thymine at the same position of the cytosine base
(which reflects unmethylated cytosine after bisulfite conversion
and PCR amplification).
Bisulfite pyrosequencing
Genomic DNA (800 ng) was modified with sodium bisulfite using
the Zymo EZ DNA methylation kit (Zymo Research Corpora-
tion, Irvine, CA, USA). For pyrosequencing of the intron 3 region
of IGF2, we amplified bisulfite modified DNA using 0.12µM
of each primer (all primers are listed in Table 1) in a 25µl
reaction containing 40 ng of bisulfite modified template DNA,
1.5 mM MgCl2 and using the PyroMark PCR Kit (Qiagen; Valen-
cia, CA, USA). Cycling conditions were 95˚C for 15 min, then
55 cycles of 94˚C for 30 s, 59˚C for 30 s, and 72˚C for 30 s, fol-
lowed by 10 min at 72˚C. Pyrosequencing was performed using
Pyromark Gold Q96 Reagents according to the manufacturer’s
recommendations (Qiagen). The sequence analyzed includes two
CpG dinucleotides; one located within the consensus CTCF
binding motif and a second CpG outside the consensus motif
(5′. . .gaccCGcagggtggctgCGtcc. . .3′; consensus underlined).
To validate the pyrosequencing assay, we used plasmids con-
taining bisulfite modified methylated and unmethylated copies of
the region analyzed, as previously described (Wong et al., 2006;
Murphy et al., 2012). The plasmid DNAs were quantified, defined
mixtures prepared, and run in quadruplicate. Pyrosequencing
assay design and validation for the IGF2 DMR was as described
previously (Murphy et al., 2012).
RNA ANALYSES
Cells were cultured until 70–80% confluent and washed with cold
PBS. Total RNA was isolated from these cells and from frozen
human conceptual tissues with RNA Stat-60 reagent (Amsbio,
Lake Forest, CA, USA). One microgram was reverse transcribed
using Superscript II according to the manufacturer’s protocol
(Invitrogen). The resulting cDNA was amplified using a Taq-
Man assay for IGF2 expression (Assay ID: Hs04188276_m1)
with a Rotor-Gene Q Real-Time PCR thermocycler (Qiagen).
Beta-2-Microglobulin (B2M ) (Assay ID: Hs00187842_m1) was
used as a control for input. Expression values were determined
using the delta delta C t method. IGF2 mRNA expression val-
ues from cell lines were obtained from our previously published
Affymetrix U133A microarray data (Gene Expression Omnibus
Accession GSE25428) and expression values were validated using
quantitative real-time RT-PCR.
PROTEIN ANALYSIS
Western blotting was performed to determine the endogenous lev-
els of CTCF protein in the ovarian cancer cell lines. Briefly, 30µg
of total cell lysate was obtained using cell lysis buffer from cells
that were cultured to 70–80% confluence (Cell Signaling). Anti-
bodies used were anti-CTCF (Millipore #07-729, diluted 1:2000)
and anti-α-Tubulin (Millipore #05-829, diluted 1:200). The anti-
mouse HRP conjugated secondary antibody (Bio-Rad; Hercules,
CA, USA) was used at a dilution of 1:3000 and the proteins
were detected with the ECL kit (GE Healthcare) following the
manufacturer’s instructions.
CHROMATIN IMMUNOPRECIPITATION
Chromatin Immunoprecipitation (ChIP) was performed with the
ChIP-It kit (Active Motif; Carlsbad, CA, USA) using 25µg of
sheared chromatin per IP and 2µg of each antibody. The rabbit
anti-human CTCF polyclonal antibody used was from Millipore
(#07-729), the anti-Brother Of the Regulator of Imprinted Sites
(BORIS) antibody was from Abcam (Ab18337; Cambridge, MA,
USA) as well as the rabbit IgG control antibody (ab37415). Real-
time PCR was performed using SYBR green reagents (Qiagen) in
an Applied Biosystems 7900HT Real-Time PCR System. Primers
are listed in Table 1. The 5′-insulator site in the c-MYC gene con-
stitutively binds CTCF and was used as a positive control for CTCF
binding as previously described (Pugacheva et al., 2005).
INSULATOR ASSAYS
The DNA fragment containing the intron 3 CTCF consensus
sequence was PCR amplified using the primers listed in Table 1.
The product was cloned into the pGL3-control Luciferase Reporter
Vector (pGL3-P-control; Promega, Madison, WI, USA) using
the Nhe1 and Xho1 restriction sites. This plasmid contains the
luciferase gene under control of the SV40 promoter with SV40
enhancer sequences located downstream. The multi-cloning site is
upstream of the SV40 promoter region. A sequence fragment from
within the GAPDH locus was also used for comparative purposes
(see Table 1). This fragment was cloned into the pGL3-P-control
using SmaI and BglII restriction sites. The recombinant plas-
mids were confirmed by restriction digestion and by nucleotide
sequencing. Constructs were named pGL3 (vector only), pGL3-
CTCF, and pGL3-GAPDH. HEY, CAOV2, and OVCAR2 cells were
grown to 70–80% confluence and transfected with the various
pGL3 plasmid constructs using FuGENE®HD reagent according
to the manufacturer’s protocol (Promega, Madison, WI, USA).
Luciferase activity was measured 48 h and 72 h post-transfection
in sextuplicate according to the protocol from the manufacturer
(Promega). Luciferase activity was normalized for cell number.
STATISTICAL ANALYSIS
All statistical analyses were performed using Prism 5 for Macintosh
(Graphpad Software, Inc.) with p values less than 0.05 considered
significant.
RESULTS
IDENTIFICATION OF A CTCF BINDING MOTIF IN IGF2 INTRON 3
The genomic structure of IGF2 is presented in Figure 1. Given
the importance of CTCF binding upstream of the H19 promoter
to the imprinting and expression of IGF2 and H19 and the ubiq-
uity of IGF2 overexpression in serous epithelial ovarian cancer
(Murphy et al., 2006), we wished to determine if there are other
CTCF binding sites within the IGF2/H19 imprinted domain that
contribute to regulation of IGF2 in this disease. By searching the
genomic sequence, we identified a binding motif within IGF2
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intron 3 having sequence matching that of the consensus motif
for CTCF binding (5′-CCGCNNGGNGGC-3′) (Wylie et al., 2000;
Rosa et al., 2005). Remarkably, the position of this motif is∼350 bp
downstream of an inverted repeat element within the same intron,
in a region that was identified as being conserved among mam-
mals that exhibit imprinted IGF2 expression (Weidman et al.,
2004). The inverted repeat has subsequently been found to encode
a microRNA, MIR483 (NR_030158.1) that has been implicated
in angiogenesis, oncogenicity, and adipose tissue programing
(Veronese et al., 2010; Qiao et al., 2011; Ferland-McCollough et al.,
2012; Ma et al., 2012).
INTRAGENIC IGF2 METHYLATION CORRELATES WITH EXPRESSION
To determine if IGF2 expression levels are associated with intra-
genic methylation of IGF2 at this region, we analyzed 35 primary
serous epithelial OVCA specimens using quantitative radiolabeled
bisulfite sequencing. We found highly variable methylation at the
region adjacent to and within the IGF2 intron 3 consensus CTCF
binding motif. Methylation of two CpGs, including one within the
core binding motif, was higher in 18 OVCAs with elevated IGF2
expression versus 10 with low expression (average 68.2% versus
38.5%; p< 0.0001) (Figure 2A). We also examined the relation-
ship between expression and methylation in a panel of tissues
from a 108 day human female conceptus, and found that most
tissues with higher methylation also had higher IGF2 expression
(gut, liver, umbilical cord, brain, pancreas and heart versus thymus,
decidua, placenta, spleen, muscle, and kidney; p= 0.03 for t test
between these groups; data presented in Figure 2B is by individ-
ual tissue for clarity). These results support that the methylation
status of these intronic CpG dinucleotides is positively associated
with IGF2 expression and may therefore be involved in regulating
levels of IGF2.
GERMLINE METHYLATION
The CpG dinucleotides within the CTCF binding motifs of the
IGF2/H19 ICR are methylated on the paternal chromosome
and this methylation profile is established during gametogene-
sis. Because the ICR and intron 3 CpGs are located greater than
100 kb apart (Figure 1), we analyzed the IGF2 intron 3 CpG sites
in 16 independent human spermatozoa specimens to determine
if these CpGs are also methylated in sperm. These and subse-
quent analyses were performed by bisulfite pyrosequencing after
validating the linear performance of the assay using defined mix-
tures of fully methylated and unmethylated DNAs (input versus
measured methylation R2= 0.99; Figure 3). We found that the
intron 3 CpG sites exhibited high levels of methylation in sperm
from all 16 individuals (Figure 4A; results from replicate mea-
sures shown). However, comparison of the two intron 3 CpGs
revealed significant differences in methylation levels despite being
located just 13 bp apart (CpG 1: mean 93.2%, SD= 1.7%; CpG
2: 79.7%, SD= 1.4%; paired t test p< 0.0001). Human fetal liver
tissue run in parallel was 58.9 and 44.0% methylated at these CpG
sites, respectively.
Analysis of human conceptual tissues from up to nine individ-
uals showed intermediate levels of methylation at these same sites
FIGURE 1 | Schematic of the IGF2/H19 imprinted domain. The IGF2/H19
imprinted domain is located at chromosome 11p15.5 and encompasses
∼170 kb. The insets show the genomic structure of the IGF2 gene (middle)
and H19 gene (bottom), adapted from the UCSC Genome Browser,
GRCh37/hg19 (Kent et al., 2002). Green ovals, CpG islands; yellow ovals,
CTCF binding sites; tall vertical lines/boxes, coding sequence; short vertical
lines/boxes, non-coding sequence. The promoters with direction of
transcription are indicated by arrows. The IGF2 locus also produces a
paternally expressed antisense transcript (IGF2AS), indicated by the purple
lines/boxes. The IGF2 intron 3 CTCF binding motif is shown as underlined
sequence with the CpG dinucleotides analyzed herein in capital letters. DMR,
differentially methylated region; ICR, imprint control region.
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FIGURE 2 | IGF2 intragenic methylation and IGF2 transcription.
(A) Methylation of the CpG within the IGF2 intron 3 CTCF binding motif (CpG
1) and adjacent CpG (CpG 2) in invasive serous ovarian cancers with very low
IGF2 expression (Affymetrix U133A MAS5 values between 9 and 71,
average=26; labeled as “low”) compared to those with higher expression
(MAS5 values between 128 and 24,056, average=5,343; labeled as “high”).
(B) IGF2 expression shown as a bar graph (+SD for replicate measures; left y
axis) as detected in tissues from a 108-day gestation human female
conceptus with the corresponding level of methylation, given as a
percentage, at the CpG within the intron 3 CTCF binding motif (right y axis,
circles±SD of replicate measures). The data are arranged from left to right in
increasing order of IGF2 expression.
FIGURE 3 |Validation of the IGF2 intron 3 region pyrosequencing
assay. Methylation was measured for both CpG dinucleotides within the
intron 3 region under study and averaged (y axis, ±SD for triplicate
measures) for defined mixtures of plasmids (x axis) containing the bisulfite
modified methylated and unmethylated intron 3 region sequences.
(Figure 4B; range 36.3–72.6%), suggesting that the methylation
in somatic tissues may be parent-of-origin-dependent, although
this was not formally determined in this study. We also ana-
lyzed the IGF2 DMR in the same spermatozoa specimens. The
IGF2 DMR and P2–P4 promoter region have previously been
reported as methylated on the maternally derived chromosome
(Issa et al., 1996; Sullivan et al., 1999), although subsequent stud-
ies have found that methylation is present on the paternally
derived chromosome (Murrell et al., 2008). We observed that
the IGF2 DMR is highly methylated in sperm (mean, 93.6%,
SD= 3.3%; N = 16; not shown), indicating that this region is
also a paternal germline methylation imprint, and together indi-
cating that the entire IGF2/H19 imprinted domain may acquire
the paternal methylation marks present in somatic tissues during
spermatogenesis.
CTCF BINDING WITHIN IGF2 INTRON 3
We performed mechanistic analyses of the intragenic CTCF bind-
ing site in three ovarian cancer cell lines, including HEY, OVCAR2,
and CAOV2. HEY cells have the lowest IGF2 transcript levels,
as do many other established ovarian cancer cell lines (Mat-
sumura et al., 2011), while the other two lines exhibit higher
IGF2 expression (Figure 5A). By pyrosequencing, methylation of
the intron 3 region was lowest (66%) in the HEY cells, while the
other lines showed >85% methylation at these CpG dinucleotides
(Figure 5B).
Chromatin immunoprecipitation was used to determine if
CTCF binds to the region containing the consensus CTCF binding
motif. As a positive control, the anti-CTCF antibody was used to
test for binding at the MYC locus, known to have high CTCF
binding activity (Pugacheva et al., 2005). ChIP results showed
enrichment of CTCF binding at the MYC CTCF binding site
relative to the no antibody control (Figure 5C).
We next examined CTCF binding to the putative CTCF con-
sensus binding sequence within IGF2. Although CAOV2 and
OVCAR2 were obtained from different sources, our testing showed
that they are genetically identical (Korch et al., 2012). Despite this,
CAOV2 has much higher endogenous CTCF mRNA transcript
levels (not shown) and protein expression as measured by West-
ern blotting than OVCAR2 (Figure 5D), providing the unique
opportunity to evaluate the role of differential CTCF expression
in these otherwise genetically identical cells. OVCAR2 cells did not
exhibit enriched binding of CTCF to the intron 3 CTCF binding
motif relative to the control, while CAOV2 and HEY showed∼2.2
to 3.8-fold enrichment of CTCF binding (Figure 5E).
BORIS BINDING AT THE IGF2 INTRON 3 CTCF SITE
We also determined if the BORIS protein (encoded by CTCFL)
binds at the CTCF motif. BORIS and CTCF are paralogs that have
the same binding specificity, with BORIS normally expressed dur-
ing spermatogenesis. BORIS has been shown to become deregu-
lated in cancers, and to compete with CTCF for binding occupancy
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FIGURE 4 | Characterization of IGF2 intron 3 CTCF binding motif
methylation in spermatozoa and human fetal tissues. (A) Measurement
of % methylation (y axis) for both CpG dinucleotides (CpG Site 1, CpG within
the CTCF binding motif; CpG Site 2, CpG adjacent to the CTCF binding motif)
in 16 individual human spermatozoa specimens (1–16 on x axis) and in human
fetal liver (FL). The results from each of two assays are shown. (B) Box and
whisker plot showing average percent methylation for the two CpG
dinucleotides in the IGF2 intron 3 region across a panel of human conceptal
tissues (boxes, 10th to 90th percentile). The number of individuals analyzed
for each tissue type is indicated.
(Klenova et al., 2002). Indeed, by ChIP, BORIS was enriched at the
intron 3 CTCF site in HEY and OVCAR2 (in which CTCF does
not bind) but BORIS was not enriched at the intron 3 CTCF site
in CAOV2 cells (Figure 5F).
REPRESSOR/INSULATOR ACTIVITY OF IGF2 INTRON 3
We used a luciferase reporter assay to determine how the presence
of the IGF2 intron 3 CTCF binding motif influences transcrip-
tional activity. We tested three constructs, including the vector
alone, the vector containing the CTCF binding motif, and the vec-
tor containing an intronic sequence from within theGAPDH locus
with similar nucleotide composition but that does not contain a
consensus CTCF binding motif. Luciferase activity was normalized
to that obtained for the pGL3 vector alone.
In all three of the cell lines, the presence of the GAPDH
sequence fragment was not inhibitory to transcription, with
increased luciferase activity relative to the vector control
(Figure 6). In the OVCAR2 and CAOV2 lines that have no or
relatively low CTCF binding activity, respectively, the presence of
the IGF2 intron 3 CTCF binding region reduced luciferase activity,
suggesting that this sequence element may function as an insulator
or repressor in these cells. In the HEY cells, which have the high-
est level of CTCF binding activity, lowest IGF2 transcription, and
lowest methylation among the three lines tested, the CTCF region
was not inhibitory to transcription.
DISCUSSION
We have identified a novel consensus binding sequence for the
CTCF protein within an intron of IGF2. The IGF2/H19 imprinted
domain contains an intensively studied cluster of CTCF binding
sites that are located upstream from the H19 promoter region.
Hypermethylation of the paternally derived allele and hypomethy-
lation of the maternally derived allele at this ICR is required for the
appropriate establishment of imprinted expression in mice, and
CTCF binding to the hypomethylated maternally derived chro-
mosome maintains the unmethylated state of this allele in somatic
tissues (Schoenherr et al., 2003; Szabo et al., 2004). CTCF bind-
ing to the orthologous region in humans may not be as critical in
regulating expression of IGF2 or H19 (Ulaner et al., 2003).
We had previously shown a positive correlation with methy-
lation at the IGF2/H19 ICR and IGF2 expression that was not
related to loss of imprinting (Murphy et al., 2006). In the present
study, we also determined that there is a significant positive cor-
relation between methylation of the intron 3 CpG sites and IGF2
transcription in serous epithelial ovarian cancers. Our assay mea-
sured methylation of two CpG dinucleotides, including one within
the CTCF consensus binding sequence and another located 13 bp
away, just outside the consensus sequence. The CpG within the
CTCF binding motif showed consistently higher methylation than
the one positioned outside the binding motif in all tissues ana-
lyzed, but the significance of this observation is presently unclear.
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FIGURE 5 | IGF2 analyses in HEY, CAOV2, and OVCAR2 ovarian
cancer cell lines. (A) IGF2 transcription levels in each cell line; (B) IGF2
intron 3 region methylation levels; (C) ChIP assay for binding of CTCF
to the MYC locus in CAOV2 and OVCAR2 cells (HEY cells were not
analyzed); (D)Western blot detection of CTCF protein levels; (E) ChIP
assay for binding of CTCF to the IGF2 intron 3 CTCF binding motif; (F)
ChIP assay for binding of BORIS to the IGF2 intron 3 CTCF binding
motif.
Regardless of the difference in methylation between the two sites
within a given tissue, they both showed higher methylation in
normal tissues and tumors with higher IGF2 transcript levels, sug-
gesting that this region may contribute to regulating IGF2 activity.
A hallmark of imprinted genes is parental allele-specific methy-
lation that is established during gametogenesis. Methylation at the
IGF2/H19 ICR is present on the paternally derived chromosome
and is one of only several regions in the human genome known
to contain a paternally derived gametic imprint mark. Most of
the methylation associated with genomically imprinted genes is
established on maternally derived chromosomes. We analyzed 16
independent human spermatozoa specimens to determine if the
methylation at the intron 3 region of IGF2 was established during
spermatogenesis. The spermatozoa all showed very high methyla-
tion of these CpG sites, indicating that the methylation is estab-
lished during spermatogenesis, and consistent with the idea that
these CpG sites may also be a component of the gametic imprint
mark for the IGF2/H19 domain. Further supporting this notion
was the finding that the IGF2 DMR is also highly methylated in
the spermatozoa, in agreement with the methylation findings in
sperm for this region from another study of infertility (Boisson-
nas et al., 2010). In human conceptal tissues, we found that the
intron 3 region had mean methylation values ranging from 39.1%
(placenta) to 66.1% (heart). These findings suggest that this region
may maintain parent-of-origin-dependent methylation in somatic
tissues.
The consensus CTCF sites at the human ICR each harbor four
CpG dinucleotides,while the novel CTCF site in IGF2 intron 3 ana-
lyzed herein contains a single CpG dinucleotide. CTCF is known
to bind to the ICR in a methylation-sensitive manner (Hark et al.,
2000; Kanduri et al., 2000). CTCF binding induces a change in
chromatin structure that results in insulator activity. Insulation
at the ICR on the unmethylated maternal chromosome creates
a blockade preventing interaction between the IGF2 promoters
from enhancers downstream of H19, thus contributing to IGF2
repression on the maternal chromosome (Bell et al., 1999; Bell and
Felsenfeld, 2000; Kanduri et al., 2000). This regulatory activity may
also involve intrachromosomal interactions within the domain
as well as interactions with matrix attachment regions (Kurukuti
et al., 2006). The methylation status of the intron 3 CTCF consen-
sus sequence and correlation with expression of IGF2 in ovarian
cancer prompted us to hypothesize that methylation status may
modulate binding of CTCF and that this in turn is influencing
transcriptional activity of IGF2. Our results suggest that methy-
lation of the single CpG dinucleotide within the IGF2 intron 3
CTCF binding motif may be inhibitory to CTCF binding.
The CTCF paralog, BORIS, has identical zinc fingers and DNA
binding specificity as CTCF, but the sequences diverge outside
the zinc fingers, conferring differences in regulatory capacities.
BORIS was reported to not be detectable in most normal tissues
due to exclusive expression of BORIS in the testis (Loukinov et al.,
2002). More recently, however, others have reported that BORIS is
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FIGURE 6 | Insulator activity of the IGF2 intron 3 CTCF binding motif in
ovarian cancer cells. Luciferase activity from various pGL3 plasmid
constructs, as a read out for the capacity of the IGF2 intron 3 sequence
motif to inhibit interactions between the enhancer and promoter of the
plasmid, is shown on the y axis (+SD) in each panel. HEY cells (A),
OVCAR2 cells (B) and CAOV2 cells (C) were analyzed in sextuplicate at 48 h
(light gray) and 72 h (dark gray) post-plasmid transfection. pGL3, control
plasmid with no insert; pGL3-GAPDH, plasmid with sequence fragment of
the GAPDH locus that does not contain a consensus CTCF binding motif;
pGL3-CTCF, plasmid with the IGF2 intron 3 CTCF binding motif.
indeed also expressed in normal tissues (Jones et al., 2011). Impor-
tantly, BORIS is abnormally activated in many different types of
cancer (Klenova et al., 2002), including gynecologic malignancies
(Risinger et al., 2007), and may compete with CTCF for binding
sites in this context.
We found a dramatically different CTCF and BORIS binding
activity at the consensus CTCF binding motif in intron 3 in genet-
ically identical CAOV2 and OVCAR2 cells, both of which express
relatively high levels of IGF2. The highest level of BORIS binding
was detected in OVCAR2 cells, which have very low CTCF protein
levels and do not exhibit detectable CTCF occupancy of the same
site (compare Figure 5F to Figures 5D,E). Conversely, the lowest
level of BORIS binding was in the CAOV2 cells, which are enriched
for CTCF binding. The HEY cells, with virtually no expression of
IGF2 mRNA and the lowest methylation of the intron 3 region,
showed enrichment of both CTCF and BORIS binding. Our results
demonstrate that CTCF and BORIS are both able to bind the IGF2
intron 3 CTCF binding motif and that this binding is associated
with differences in methylation and expression.
Results from a luciferase reporter assay showed that the pres-
ence of the IGF2 intron 3 CTCF binding motif had no effect on
luciferase transcription in HEY cells, while it was inhibitory to
transcription in both OVCAR2 and CAOV2 cells. Taken together,
our results are perhaps most parsimonious with the idea that
methylation of the intron 3 CTCF binding motif is inhibitory
to CTCF/BORIS binding at the endogenous locus but permis-
sive for binding in the context of the (presumed unmethylated)
reporter construct. Furthermore, these results suggest that this
region indeed has insulator function when unmethylated and
bound to CTCF or BORIS, as is the case for the reporter con-
struct in the CAOV2 and OVCAR2 cells, respectively. In the HEY
cells, CTCF and BORIS may compete with each other for binding
the intron 3 CTCF binding motif in the reporter construct with
a net null outcome. These results contrast with those observed
at the endogenous locus in these same cells, which differ at least
in part by methylation status. The CAOV2 and OVCAR2 cells
have high methylation at the intron 3 CTCF binding motif and
express IGF2 at high levels, indicative of at least partial inhibition
of CTCF or BORIS binding and low insulator activity function. In
contrast, HEY cells have lower methylation, do not express IGF2
and exhibit binding of both CTCF and BORIS to the intron 3
CTCF binding motif. These results support the idea that lower
levels of methylation are permissive for CTCF/BORIS binding,
which leads to insulation of the IGF2 promoter(s) from enhancer
activity. This is in agreement with the findings in vivo, where high
levels of methylation at the intron 3 CTCF binding motif are corre-
lated with higher levels of IGF2 transcription in both normal and
malignant tissues. Indeed, mouse studies have shown that pater-
nal methylation at an intragenic differentially methylated region of
Igf2 (referred to as DMR2) is associated with increased transcrip-
tion (Murrell et al., 2001). However, unlike the human IGF2 intron
3 CTCF binding motif analyzed here, the core Igf2 DMR2 region
in the mouse is located within an exon and is densely populated
with CpGs dinucleotides.
A limitation of our study is that we did not measure the bind-
ing of CTCF or BORIS within the reporter construct, so we do
not know if the results obtained are indeed consequent to binding
of the endogenous proteins to the reporter construct. Further-
more, it was not possible to directly test how methylation of
the CpG sites within and adjacent to the intron 3 CTCF motif
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inserted into the reporter construct might have influenced protein
binding and luciferase activity. It is possible that binding of these
proteins at the endogenous locus in CAOV2 or OVCAR2 occurs
only on the 10–15% of alleles within the cell population lacking
methylation. Our results show enrichment of binding of CTCF
or BORIS in CAOV2 and OVCAR2 cells, respectively, but do not
address what proportion of the alleles are actually bound by these
proteins.
In conclusion, elevated IGF2 expression in epithelial ovarian
cancers is associated with increased methylation of a novel reg-
ulatory sequence motif that we have shown binds to the CTCF
protein. The growth-stimulatory function of IGF2 likely confers
a substantial advantage to malignant cells, given the ubiquity of
IGF2 overexpression in ovarian cancer. Elucidation of the mech-
anisms that control IGF2 transcription is necessary if we hope
to target this gene therapeutically. Positive correlation between
methylation and IGF2 transcription in primary ovarian cancers
suggests the potential for epigenetic therapies in controlling IGF2
overexpression in this disease.
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